Predictions of widespread problems based on this ten-year-old article have since been shown by vast experience with commercial crops to be incorrect. Commercialized biotech varieties go through more screening and scrutiny, in advance, in depth and detail, than any other new crop varieties in history. The sort of instability alleged, which does happen rarely during product development, is routinely eliminated by companies for obvious reasons. In fact, data demonstrating stable Mendelian inheritance of the transgene are required as a matter of law by regulators.